메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

'김갑성' 기자의 전체기사

Medit Link Express for iPad Debuts as Medit i900 Mobility Goes…

SEOUL, South Korea, Sept. 15, 2025 -- Medit (www.medit.com), a global leader in digital dentistry, today announced two milestone moments for the industry. The company has officially launched Medit Link Express, its first iPad-native app for intraoral scanning, now available on the Apple App Store, and at the same time begun shipping the Medit i900 Mobility, previously available for pre-order since August 1. With the Medit i900 Mobility now shipping in select regions, dental professionals can experience a new level of mobility in scanning. Designed for today's clinical e
- 김갑성 기자
- 2025-09-15 19:00
Sunsred Launches FDA-cleared Red Light Therapy Device…

SHENZHEN, China, Sept. 15, 2025 -- Shenzhen Sunsred Technology Co., Ltd. is shaking things up in the wellness tech world with its latest lineup of red light therapy devices. As a go-to OEM/ODM red light therapy manufacturer in this space, Sunsred is meeting the huge global demand for safe, effective, and certified light therapy solutions. The new range includes everything from LED face masks and flexible therapy belts to versatile light panels, all built for easy customization. This gives health, beauty, and wellness brands a strong advantage in a crowded market. Red Light Ther
- 김갑성 기자
- 2025-09-15 19:00
Clinically Proven Human Milk Probiotic LC40® supports Infant He…

SINGAPORE, Sept. 15, 2025 -- Supported by six clinical studies and two safety trials, Kerry's LC40® is the first probiotic strain of its kind validated for both infant and maternal applications, offering a natural, science-backed approach to early life and maternal health. Human Milk Probiotics are strains of beneficial bacteria, specifically including Lactobacillus and Bifidobacterium, naturally found in breast milk. Kerry, in collaboration with the Complutense University of Madrid, is the first to isolate these strains, including LC40® and BfM26®, using an
- 김갑성 기자
- 2025-09-15 18:20
Akeso Announces First Patient Dose in Global Registrational…

HONG KONG, Sept. 15, 2025 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, in combination with lenvatinib versus lenvatinib alone for the treatment of advanced hepatocellular carcinoma (HCC) in patients previously treated with atezolizumab (a PD-L1 inhibitor) and bevacizumab. COMPASSION-36 is the first global registrational Phase
- 김갑성 기자
- 2025-09-15 12:11
Jointly discovered KAT6i molecule originating from Australian…

[ 메디채널 김갑성 기자 ] Australian scientists who discovered how to "turn off" genes that make cancer cells grow are celebrating the next phase of development – with Pfizer's first in class KAT6 inhibitor PF-07248144 now moving to the next stages of clinical investigation. MELBOURNE, Australia, Sept. 15, 2025 -- Australian biotechnology investment and commercialisation incubator, Oncology One Pty Ltd, is pleased to report that PF-07248144, Pfizer Inc's clinical drug candidate discovered from Oncology One's out-licensed KAT6 inhibitor program, has now commenced a Phase 3 clinical tr
- 김갑성 기자
- 2025-09-15 12:06
New Data, iCARE Study: Hailie® Smartinhaler® Powers Unpreced…

Highlights: Up to 235% increase in real-world adherence compared to published norms (20–40%), across ~850 chronic obstructive pulmonary disease (COPD) and asthma patients. >60% patients achieved an average two-week baseline adherence with ~4 in 10 patients reaching the critical threshold of >80% adherence, a level associated with 50% fewer exacerbations and lower hospitalisations. Sustained engagement of 12+ months with 54% persistence even in high-risk, elderly patients, far above typical digital health benchmarks (30–45%). Clinically meaningful reductions in admissions,
- 김갑성 기자
- 2025-09-15 12:05
MGI Tech Introduces DNBSEQ-T7+: A Next-Generation 'Data Min…

SHENZHEN, China, Sept. 15, 2025 -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, announced the launch of the DNBSEQ-T7+, its latest high-throughput sequencer. Designed to meet the rising demand for large-scale genomic research, the T7+ delivers more than 14 Tb/day of data in just 24 hours while offering a smaller footprint, flexible run configurations, and end-to-end automation. Internally dubbed a "data mining machine," the T7+ redefines high-throughput sequencing by combining daily output wit
- 김갑성 기자
- 2025-09-15 11:53
EverBridge Group and Cosmotec Forge Landmark Partnershi…

SHANGHAI, Sept. 15, 2025 -- EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market. This strategic collaboration underscores EverBridge Group's leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence. Simultaneously, the partnership underscores Cosmotec's best-in-class digital commercialization platf
- 김갑성 기자
- 2025-09-15 08:00
Lion TCR Achieves Triple FDA Milestones with IND Clearance fo…

SINGAPORE and GUANGZHOU, China, Sept. 15, 2025 -- Lion TCR, a clinical-stage biotechnology company pioneering T-cell receptor (TCR)-based therapies, today announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate phase1b/2 clinical trials for its proprietary TCR-T cell therapy, LioCyx-M004, in patients with chronic hepatitis B (CHB). This approval represents the third major regulatory milestone for the same product candidate, which previously received both Fast Track and Orphan Drug Designations for the treatme
- 김갑성 기자
- 2025-09-15 08:00
Phrontline Biopharma Announces First Patient Dosed in Pha…

SHANGHAI and SUZHOU, China, Sept. 15, 2025 -- Phrontline Biopharma, a clinical-stage biotechnology company advancing a new generation of Antibody-Drug Conjugates (ADCs), today announced that the first patient has been successfully dosed in its Phase 1 clinical trial of TJ101, the company's lead asset targeting EGFR/B7-H3 with a proprietary linker-drug technology. "This is a critical milestone for Phrontline as we advance our mission to deliver innovative ADC therapies that can meaningfully impact patients' lives," said Zhaoyuan "Tony" Chen, Chief Executive Officer o
- 김갑성 기자
- 2025-09-15 08:00

이전

41 42 43 44 45 46 47 48 49 50

많이 본 기사

최근기사

2025-10-21_TUE

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 10월 22일 01시 00분